Web Analytics Made Easy - StatCounter
Category

Nervous System Diseases

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Read More

Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample.

By | Brain Disorders, Cardiovascular Diseases, Medical Cannabis, Nervous System Diseases

Authors: Aditi Kalla, Parasuram Krishnamoorthy, Akshaya Gopalakrishnan, Vincent Figueredo
Journal of Cardiovascular Medicine, September 2018

BACKGROUND: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a…

Read More

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

By | Brain Disorders, Epilepsy, Medical Cannabis, Nervous System Diseases

Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, et al
Journal of Neurology, Neurosurgery & Psychiatry, July 2018

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerab…

Read More

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018

Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

Read More

Cannabis in Parkinson’s Disease: Hype or help?

By | Medical Cannabis, Nervous System Diseases, Parkinsonian Disorders

Authors: Tina Mainka, Jan Stork, Ute Hidding, Carsten Buhmann
Fortschritte der Neurologie · Psychiatrie, February 2018

Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies.The prescription of medical marihuana is not restricted to specific symptoms…

Read More

A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders.

By | Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases

Authors: Keane Lim, Yuen Mei See, and Jimmy Lee
Clinical Psychopharmacology and Neuroscience, 30 November 2017

The discovery of endocannabinoid’s role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The present review aimed to synthesize and evaluate the available evidences on the e…

Read More

Medical Cannabis in Parkinson Disease: Real-Life Patients’ Experience.

By | Medical Cannabis, Nervous System Diseases, Parkinsonian Disorders

Authors: Yacov Balash, Lihi Bar-Lev Schleider, Amos Korczyn, Herzel Shabtai, Judith Knaani, et al
Clinical Neuropharmacology, November/December 2017

BACKGROUND: The use of medical cannabis (MC) is controversial. Support for its benefits is based on small clinical series. OBJECTIVE: The aim of this study was to report the results of a standardized interview study that retrospectively assessed the effects of MC on symptoms o…

Read More

Endocannabinoid system in neurodegenerative disorders.

By | Neurodegenerative Diseases

Authors: Balapal S. Basavarajappa, Madhu Shivakumar, Vikram Joshi, Shivakumar Subbanna
Journal of Neurochemistry, September 2017

Most neurodegenerative disorders (NDDs) are characterized by cognitive impairment and other neurological defects. The definite cause of and pathways underlying the progression of these NDDs are not well-defined. Several mechanisms have been proposed to contribute to the develo…

Read More

Cannabinoids in treatment-resistant epilepsy: A review.

By | Brain Disorders, Epilepsy, Medical Cannabis, Nervous System Diseases

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

Read More

Cannabinoids in Parkinson’s Disease.

By | Nervous System Diseases, Parkinsonian Disorders

Authors: Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, Ennio Iezzi
Cannabis and Cannabinoid Research, February 2017

The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably compl…

Read More